| SOLV |
Report |
Total Revenue |
BEAT |
pred ~$2.21B vs. cons $2.17B |
MEDIUM |
| SOLV |
Report |
Adjusted EPS |
BEAT |
pred ~$1.98 vs. cons $1.91 |
MEDIUM |
| SOLV |
Report |
Organic Sales Growth (reported, incl. ERP pull-forward) |
BEAT |
pred ~5.0% vs. cons ~3.5% |
MEDIUM |
| SOLV |
Guide |
FY2026 Adjusted EPS Guidance |
UNCHANGED |
guide ~$6.55 vs. cons $6.58 (FY2026) |
MEDIUM |
| SOLV |
Guide |
Q3 2026 Organic Growth (post pull-forward reversal) |
LOWER |
guide ~-2% vs. cons ~+3.0% (Q3 2026) |
HIGH |
| SOLV |
Guide |
FY2026 Adjusted Operating Margin Guidance |
UNCHANGED |
guide ~21.2% vs. cons ~21.2% (FY2026) |
MEDIUM |
| SOLV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| SOLV |
Return |
5-day cumulative residual |
-5.5% (FADE) |
Stock has already rallied ~25-30% off spring lows and ~14% just in the two weeks pre-print (Trian stake, multiple sell-side upgrades to $90-95 PTs), pricing in a clean beat-and-raise. Even with a likely EPS/revenue beat driven by the pre-announced >$100M ERP-related order pull-forward, that benefit is a known, one-time timing item that mechanically reverses in Q3 - sell-side models will need to explicitly cut Q3 organic growth/revenue estimates (implied ~-2% vs. prior run-rate expectations), which typically shows up as negative forward EPS revisions even after a Q2 'beat.' With guidance likely just reaffirmed (not raised) at the top of the existing $6.40-6.60 range, the bar set by the stock's run and elevated options-implied move argues for initial profit-taking on the print (Day 1) that continues to fade over the following days as analysts true-up FY2026/Q3 models for the reversal and flag the Q3 US ERP cutover as a fresh, unhedged execution risk. |
MEDIUM |